Antoine Mouche1, Cyrielle Parmentier1,2, Claire Herbez Rea1,2, Thérèsa Kwon3, Olivia Boyer4, Jean Daniel Delbet1, Tim Ulinski5,6. 1. Pediatric Nephrology Unit, Armand Trousseau Hospital, APHP, DMU Origyne, Sorbonne Université, 75012, Paris, France. 2. Sorbonne Université, Paris, France. 3. Pediatric Nephrology Unit, Robert Debré Hospital, APHP, Paris, France. 4. Pediatric Nephrology Unit, Necker Enfants Malades Hospital, APHP, Paris, France. 5. Pediatric Nephrology Unit, Armand Trousseau Hospital, APHP, DMU Origyne, Sorbonne Université, 75012, Paris, France. tim.ulinski@aphp.fr. 6. Sorbonne Université, Paris, France. tim.ulinski@aphp.fr.
Abstract
BACKGROUND: Infections are responsible for morbidity and mortality in children on hemodialysis (HD). Procalcitonin (PCT) is rarely used in this population, even though it is an efficient biomarker of infection and sepsis. Our aim was to study PCT baseline level in uninfected children with stage 5 chronic kidney disease (CKD 5) on HD, and determine how to use it in this population. METHODS: Prospective observational study including 40 uninfected children on classical HD or hemodiafiltration (HDF) in three pediatric HD centers in the Paris region. PCT was monitored before and after three consecutive sessions within 1 week. RESULTS: Median pre-dialysis PCT was 0.60 ng/mL [0.36-1.15], median post-dialysis PCT was 0.23 ng/mL [0.10-0.47], PCT reduction rate was 59.8% [37.5-75.8]. Seventy percent of pre-dialysis PCT were <1 ng/mL. Anuric patients had higher pre-dialysis PCT than those with residual urine output (0.70 [0.42-1.30] vs. 0.48 [0.30-0.93] ng/mL, p=0.01). HDF was more efficient than HD to clear PCT during sessions (reduction rate 75% [67-80] vs. 37 [31-50]), p<0.001). CONCLUSION: PCT levels in pediatric HD patients without infection are higher than normal, but this increase is relatively moderate compared to massive increases of PCT in children with bacterial infections on HD. If PCT is measured after dialysis sessions, the specific technique-dependent reduction rates should be taken into consideration. Moderately increased PCT levels around 2 ng/ml should be interpreted with caution; however, higher PCT serum levels can be used to motivate rapid start of antibiotic treatment in pediatric HD patients.
BACKGROUND: Infections are responsible for morbidity and mortality in children on hemodialysis (HD). Procalcitonin (PCT) is rarely used in this population, even though it is an efficient biomarker of infection and sepsis. Our aim was to study PCT baseline level in uninfected children with stage 5 chronic kidney disease (CKD 5) on HD, and determine how to use it in this population. METHODS: Prospective observational study including 40 uninfected children on classical HD or hemodiafiltration (HDF) in three pediatric HD centers in the Paris region. PCT was monitored before and after three consecutive sessions within 1 week. RESULTS: Median pre-dialysis PCT was 0.60 ng/mL [0.36-1.15], median post-dialysis PCT was 0.23 ng/mL [0.10-0.47], PCT reduction rate was 59.8% [37.5-75.8]. Seventy percent of pre-dialysis PCT were <1 ng/mL. Anuric patients had higher pre-dialysis PCT than those with residual urine output (0.70 [0.42-1.30] vs. 0.48 [0.30-0.93] ng/mL, p=0.01). HDF was more efficient than HD to clear PCT during sessions (reduction rate 75% [67-80] vs. 37 [31-50]), p<0.001). CONCLUSION: PCT levels in pediatric HD patients without infection are higher than normal, but this increase is relatively moderate compared to massive increases of PCT in children with bacterial infections on HD. If PCT is measured after dialysis sessions, the specific technique-dependent reduction rates should be taken into consideration. Moderately increased PCT levels around 2 ng/ml should be interpreted with caution; however, higher PCT serum levels can be used to motivate rapid start of antibiotic treatment in pediatric HD patients.
Authors: S Herget-Rosenthal; G Marggraf; F Pietruck; J Hüsing; M Strupat; T Philipp; A Kribben Journal: Nephrol Dial Transplant Date: 2001-05 Impact factor: 5.992
Authors: Martin Stocker; Wendy van Herk; Salhab El Helou; Sourabh Dutta; Matteo S Fontana; Frank A B A Schuerman; Rita K van den Tooren-de Groot; Jantien W Wieringa; Jan Janota; Laura H van der Meer-Kappelle; Rob Moonen; Sintha D Sie; Esther de Vries; Albertine E Donker; Urs Zimmerman; Luregn J Schlapbach; Amerik C de Mol; Angelique Hoffman-Haringsma; Madan Roy; Maren Tomaske; René F Kornelisse; Juliette van Gijsel; Eline G Visser; Sten P Willemsen; Annemarie M C van Rossum Journal: Lancet Date: 2017-07-12 Impact factor: 79.321
Authors: Nicholas Chesnaye; Marjolein Bonthuis; Franz Schaefer; Jaap W Groothoff; Enrico Verrina; James G Heaf; Augustina Jankauskiene; Viktorija Lukosiene; Elena A Molchanova; Conceicao Mota; Amira Peco-Antić; Ilse-Maria Ratsch; Anna Bjerre; Dimitar L Roussinov; Alexander Sukalo; Rezan Topaloglu; Koen Van Hoeck; Ilona Zagozdzon; Kitty J Jager; Karlijn J Van Stralen Journal: Pediatr Nephrol Date: 2014-07-21 Impact factor: 3.714
Authors: Wan Soo Lee; Dae Woong Kang; Jong Hun Back; Hyun Lee Kim; Jong Hoon Chung; Byung Chul Shin Journal: Korean J Intern Med Date: 2015-02-27 Impact factor: 2.884